Your browser doesn't support javascript.
loading
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Stork, Martin; Spicka, Ivan; Radocha, Jakub; Minarik, Jiri; Jelinek, Tomas; Jungova, Alexandra; Pavlicek, Petr; Pospisilova, Lenka; Sedlak, Frantisek; Straub, Jan; Pika, Tomas; Knechtova, Zdenka; Fidrichova, Anna; Boichuk, Ivanna; Sevcikova, Sabina; Maisnar, Vladimir; Hajek, Roman; Pour, Ludek.
Afiliação
  • Stork M; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
  • Spicka I; 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic.
  • Radocha J; 4th Department of Medicine - Hematology, Faculty of Medicine, Charles University Hospital, Hradec Kralove, Czech Republic.
  • Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University Olomouc, Olomouc, Czech Republic.
  • Jelinek T; Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
  • Jungova A; Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic.
  • Pavlicek P; Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Pospisilova L; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Sedlak F; 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic.
  • Straub J; 1st Medical Department - Clinical Department of Hematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic.
  • Pika T; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University Olomouc, Olomouc, Czech Republic.
  • Knechtova Z; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
  • Fidrichova A; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
  • Boichuk I; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic.
  • Sevcikova S; Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Maisnar V; 4th Department of Medicine - Hematology, Faculty of Medicine, Charles University Hospital, Hradec Kralove, Czech Republic.
  • Hajek R; Department of Hematooncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
  • Pour L; Department of Internal Medicine, Hematology and Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czech Republic. Pour.ludek@fnbrno.cz.
Ann Hematol ; 102(6): 1501-1511, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37088816
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: República Tcheca
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Ann Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: República Tcheca